Sign in

Research summary ·

American Society of Hematology 2026 guidelines for immune thrombocytopenia: initial and second-line therapy for adults with primary ITP.

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

This is a guideline from the American Society of Hematology, or ASH. It updates the group's 2019 advice on immune thrombocytopenia, called ITP. It covers adults with primary ITP. A panel of experts wrote it, with 2 patient members. They looked at reviews of the research up to 19 July 2025. They used a set method, called GRADE, to judge the evidence.

What they found

The panel agreed on advice for the first treatment of adults with ITP. They also gave advice for when steroid drugs used first did not work. They added good practice notes on switching between thrombopoietic drugs. They also gave notes on surgery to take out the spleen.

What it means for patients

For first treatment, the guideline says doctors can add a second drug to steroids. This could be rituximab or a thrombopoietic drug, not steroids alone. The panel rated this advice as conditional, not strong. If steroids used first did not work, doctors can use a thrombopoietic drug. The panel rated this advice as strong. Rituximab is another option here, with conditional advice.

Why it is not certain yet

Some of the advice is conditional, not strong. The abstract does not give the results of the evidence reviews. It does not say how good the evidence was for each question. A guideline can only be as good as the studies behind it.

Source

American Society of Hematology 2026 guidelines for immune thrombocytopenia: initial and second-line therapy for adults with primary ITP.

PubMed · PMID 42617047

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Immune thrombocytopenia (ITP) publications